Mass.-based Biogen will shut down its controversial Alzheimer's drug
Biogen will stop developing its Alzheimer’s treatment Aduhelm, a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.
Source: wcvb.com